AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Ask for an EKG if you’re on hormone therapy – Dr. Alfredo says it’s cheap!
Topics Discussed
Newbie switches ADT after EKG; wearing a Holter patch; white diet during radiation; AnCan’r signs up for ANDROMEDA; 8 lesions but all above the pelvis call for new QB; no treatment for 12 mo. more, so why worry about what’s available; T returns and PSA says low; Axumin may find what PSMA does not; dental issue; insist on regular DEXA and PSMA scans during treatment; PTEN and TP53 somatic emerge – will it change treatment?; MSKCC doc drops the ball; steady as she goes on mono daro at 89; E2 needs name for its newsletter
Chat
Billy Ingersoll sent: 3:23 PM
QTC 482 from 420/437
Alfredo in Sacramento sent: 3:26 PM
Medicare covers 72% of the EKG (Electrocardiogram) cost. Beneficiaries should budget approximately $4 in out-of-pocket costs. EKG (Electrocardiogram) costs vary 37% across states: from $12 in Arkansas to $17 in Alaska. At $15 nationally, EKG (Electrocardiogram) is a low-cost procedure. For most Medicare beneficiaries, the coinsurance will be under $50. The patient cost of $4 is within the annual Part B deductible ($257), making this relatively affordable for Medicare beneficiaries.
Jim Marshall, Vet Sup Grp. Moderator sent: 3:46 PM
There is GOTO Help. 877-582-7011 if want to ask why. Jim
Avery Becton sent: 3:46 PM
ok. thx
Avery Becton sent: 3:51 PM
Finally I can hear the group on my PC
Bob Schwartz, USN, Venice, FL. sent: 3:58 PM
Great mtg., see everyone next mtg., have to go.
Alfredo in Sacramento sent: 3:58 PM
Gotta go now, best wishes to all.
AnCan–John A sent: 4:11 PM
next-generation sequencing or genomic or somatic test .on the biopsy sample
Jim Marshall, Vet Sup Grp. Moderator sent: 4:12 PM
Genitourinary Medical Oncologist
David D Seattle sent: 4:51 PM
I have to run to another meeting. Have a good evening all.
Alan Moskowitz sent: 4:56 PM
bye all
J. Ward sent: 4:59 PM
What was the date of Len’s write-up again, please?
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: No Newbies – but repeating topics: incontinence; heart issues; and, intermittent vs continuous hormone therapy
Topics Discussed
Foamy gland AnCan’r does well with Pluvicto but has urinary issues; incontinence issues defer salvage RT; PCPEP program solid but time consuming; AnCan’r getting AUS this week; neck fan outperforms venlafaxine for hot sweats; low T and still hot sweats; Gent on abi cuts back his prednisone and has muscle pains; are cardio issue down to oncology treatments/; after 24 mo doublet, is it time for a change?; Dr. E’s available to sort his protocol – our AnCan’r just has to call; ending HT takes time to reverse the side effects
SDHA sig for paragangliomas (noncancerous) and GI stromal tumors, and pheos. We need not be concerned it looks like
Len Sierra sent: 6:18 PM
From the AnCan website, my comments from 2024: Tumor responses improved following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264443/ Conclusions: Durable PSA responses occur in up to 40% of patients following a ‘steroid switch’ for PSA progression on abiraterone and prednisone
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: LDR recurrence requires HDR follow-up. Low meeting demand leads to many open-mic Qs.
Topics Discussed
Focal HIFU therapy recurs as 3+3 in gland – which group to attend?; our military chaplain is stable but needs VA help; Frank very happy with AnCan’s GU med onc match; treating LDR brachy recurrence with HDR and SBRT; seeking next line of systemic treatment that’s not chemo or PSMA driven; spot RT for skull Mx; low tech swamp cooler hangs around the neck; old ivermectin/fenbendazole chestnut booted; 6x Pluvicto successfully completed; strategy for next chemo session; oxybutynin for hot flashes; E2 patch does not cause leg DVT; germline Gent questions need for counseling
Chat
Bob Schwartz, USN, Venice, FL sent: 3:45 PM
Frank, you help as much as you get help. Don’t ever doubt how much we appreciate you.
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Toss up between ANDROMEDA trial and dormant cancer discussion
Topics Discussed
T3b Gent needs clarification on his Bx before starting treatment; how much HT before discussing intermittent; starting doublet; Nagar suggests IMRT is better for this Gent; switching HT drugs may address castrate resistance; Cialis for nocturia – maybe; potential cardio-onc in Portland, OR; Kishan’s ANDROMEDA trial attractive to men with slow recurrence; can prostate cancer cells be dormant?… follow up post-recording suggests YES.
Chat
AnCan – Rick sent: 4:58 PM
RJ – please call 877 582 7011 for HELP!!
Dial In 646 749 3129 #222 583 973
Jeff Marchi – San Francisco sent: 5:23 PM
Rajni Sethi is a Radiation Oncologist
Jim Marshall, Vet Support Grp. Moderato sent: 5:33 PM
Dr Jonathan Epstein. Advanced Uropathology of New York 700 Stewart Ave, Suite 101 Garden City, NY 11530 Hours: Monday-Friday 9:00AM – 6:00PM P: 516-760-2037 F: 516-200-3899 jepstein@imppllc.com
Jeff Marchi – San Francisco sent: 5:36 PM
orgovyx
Jeff Marchi – San Francisco sent: 5:38 PM
Ductal is very aggressive, is it really Ductal
Jeff Marchi – San Francisco sent: 5:39 PM
that would call for 2nd
Bob Schwartz, USN, Venice, FL. sent: 5:44 PM
Veterans, in Capt. Jim, We Trust!
Jim Marshall, Vet Support Grp. Moderator sent: 5:45 PM
Jim Marshall, USAF(RET), 703-338-7341. veterans@ancan.org
May be a GU cardiologist: Maros Ferencik OHSU Knight Cardiovascular Institute Cardiology Clinic, Beaverton, OR 1-503-494-1775
Jeff Marchi – San Francisco sent: 6:49 PM
Actinium major problem with dry mouth
Jeff Marchi – San Francisco sent: 6:50 PM
more according to studies
10-25%have severe dry mouth
Larry (Alaska-Estradiol as ADT monotherapy) sent: 6:52 PM
Alpha particles simply have a shorter penetration than beta particles, so cellular damage is more limited to the locations the ligand binds the radioactive material. The problem with both is that the radioactive material is placed everywhere there is uptake of the ligand.
Joseph (Sean) Siry – Laguna Woods, CA. sent: 6:52 PM
So the actinium treatment does not rely on knowing the precise location of the metastasis?
Larry (Alaska-Estradiol as ADT monotherapy) sent: 6:53 PM
Joseph/Sean, both treatments (using ligands) bind to the same cells. The ligand (sort of) “knows” where to bind.
Joseph (Sean) Siry – Laguna Woods, CA. sent: 6:59 PM
my Testosterone is in the 180 + level, would systemic treatment rule me out due to ADT is just started?
